Continuous-rate infusion thrombolysis in acute feline aortic thromboembolism

The goal of this trial, “Continuous-rate infusion thrombolysis with tissue plasminogen activator, pentoxifylline, and cyproheptadine in acute feline aortic thromboembolism (ALPEXC trial),” is to investigate a treatment protocol to optimize clot dissolution in acute aortic thromboembolism in cats (“saddle thrombus”) using a constant infusion of a clot buster (tissue plasminogen activator [TPA or alteplase]) and mitigate side effects of treatment such as acute kidney injury and reperfusion injury.

The study pays for all treatments and monitoring done specifically for the study, an approximately $1,500 value.


aortic thromboembolism

eligibility information

  • Cat
  • Diagnosis of feline aortic thromboembolism (FATE) with at least 2 limbs affected
  • Known onset of acute FATE within the past 3.5 hours
  • Cardiogenic FATE (LA:Ao>1.6)
  • Ability to start the study drug within 1 hour of presentation to the clinic

Enrollment Deadline

Enrollment ends February 28, 2024

contact information

If interested in enrolling, please contact the main hospital line at (970) 297-5000 to discuss eligibility with the emergency/urgent care or critical care clinician on duty. As timing is important, you may call the hospital while the cat is already on its way to the Veterinary Teaching Hospital.

CSU ram head with green background
James L. Voss Veterinary Teaching Hospital

Main Hospital Line: (970) 297-5000